Bruker Corporation $BRKR Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. trimmed its stake in Bruker by 1.4%, selling 144,437 shares in Q4 and leaving it with 10,259,824 shares (about 6.75%) valued at roughly $483.34 million.
• Bruker beat quarterly expectations, reporting EPS of $0.31 vs. $0.23 and revenue of $823.4M vs. $796.1M, and set FY2026 guidance at $2.10–$2.15 EPS (consensus ~2.12).
• The street consensus is a "Hold" with an average price target of $49.38; shares recently traded near $38.01 with a 52‑week range of $28.53–$56.22 and a market cap of about $5.79B.

Vanguard Group Inc. decreased its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 1.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,259,824 shares of the medical research company's stock after selling 144,437 shares during the quarter. Vanguard Group Inc. owned about 6.75% of Bruker worth $483,340,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BRKR. Royal Bank of Canada increased its position in shares of Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after purchasing an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Bruker in the first quarter valued at about $262,000. Goldman Sachs Group Inc. boosted its stake in Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after buying an additional 758,301 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock valued at $15,285,000 after acquiring an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth increased its position in shares of Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock valued at $469,000 after acquiring an additional 6,008 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the business's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company's stock, valued at $5,124,875.70. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BRKR. Barclays decreased their price objective on shares of Bruker from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Tuesday, April 14th. The Goldman Sachs Group cut their target price on Bruker from $40.00 to $35.00 and set a "sell" rating on the stock in a research report on Friday, February 13th. Jefferies Financial Group set a $50.00 price target on Bruker in a research note on Thursday, February 12th. Guggenheim lowered their price target on Bruker from $58.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, March 30th. Finally, Citigroup cut their price objective on Bruker from $53.00 to $40.00 and set a "neutral" rating on the stock in a report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Bruker currently has a consensus rating of "Hold" and an average price target of $49.38.

Bruker Price Performance

Shares of BRKR opened at $38.01 on Wednesday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $56.22. The firm's 50 day moving average price is $37.13 and its 200 day moving average price is $41.99. The company has a market cap of $5.79 billion, a P/E ratio of -253.40, a PEG ratio of 2.18 and a beta of 1.12. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to analysts' expectations of $796.11 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a $0.05 dividend. The ex-dividend date was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker's dividend payout ratio (DPR) is -133.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.